Investment bank analysts think both of these stocks have what they need to deliver big gains in the foreseeable future.
Moderna has refused to hand over to China the core intellectual property behind the development of its breakthrough Covid-19 vaccine, leading to a collapse in negotiations on its sale there, according to multiple people familiar with the matter. The Massachusetts-based pharmaceutical company turned down Beijing’s request to hand over the recipe for its messenger RNA vaccine because of commercial and safety concerns, said two people involved in negotiations that took place between 2020 and 2021. The vaccine maker says it is still “eager” to sell the product to China.
Moderna (NASDAQ: MRNA) is the name behind one of last year's top-selling pharmaceutical products. Does that mean Moderna's sales will plunge? In fact, Moderna's best days may not be in the past -- but in the future.